Tissue Regenix Group PLC Tissue Regenix announces launch of DermaPure in US (3995J)
June 12 2014 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 3995J
Tissue Regenix Group PLC
12 June 2014
Tissue Regenix Group plc
Tissue Regenix announces launch of DermaPure(TM) in the USA
-- DermaPure(TM) targets $1.4 billion a year market for skin substitutes
-- Distribution network now covers 80% of country
-- Federal institution distributor appointed
YORK, 12 June 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue
Regenix" or "the Group"), the regenerative medical devices company,
today announces that it has launched DermaPure(TM) ("DermaPure")
its decellularised dermis product in the US. Tissue Regenix's
partner CTS (Community Tissue Services) will begin shipping product
to customers next week.
In addition to the launch of DermaPure(TM), the Group also
announces that it has continued to expand its distribution network
around the country and currently has a network of over 60 reps that
covers 80% of the US. Through this network, sale representatives
will actively promote Tissue Regenix's dCELL(R) human dermis in
acute care hospitals, Veteran Affairs (VA) Hospitals and
institutions, as well as in Long Term Acute Care hospitals
(LTACs).
Furthermore, Tissue Regenix has also signed an exclusive
government supplier partnership with TASSMA for the distribution of
DermaPure(TM). TASSMA provides business development services to
medical device and equipment manufacturers seeking to rapidly grow
their federal government market share. The partnership with TASSMA
will allow Tissue Regenix to immediately target the Department of
Veteran's Affairs Healthcare System and the numerous branches of
the US military.
The commercial launch of the DermaPure(TM) dermis allograft will
now allow Tissue Regenix to target a market worth $1.4bn a year for
wound healing devices and equipment. 6.5 million US patients are
afflicted by chronic wounds currently.
Tissue Regenix's DermaPure(TM) works by taking human donor skin
and removing the DNA and cells, using the patented dCELL(R) process
to leave a natural biological scaffold that can be placed in the
wound to aid natural healing by attracting the patient's own cells
to the wound area.
A trial in the UK has shown that patients who have had chronic
wounds for an average of 4 1/2 years and who were treated with a
single application of Tissue Regenix' DermaPure(TM) have seen an
87% reduction in the size of all wounds, while 60% of patients were
completely healed, with virtually no recurrences.
DermaPure(TM) can be easily administered in hospital and/or
community settings, such as GP clinics, and is stored at room
temperature, requiring no rehydration before use or expensive
refrigerated storage.
Greg Bila, President of Tissue Regenix Wound Care Inc. said:
"Commercial production and distribution of the DermaPure(TM) is a
significant step forward for Tissue Regenix. This paves the way for
the development of other human tissue based medical treatments.
DermaPure(TM) is initially being targeted at acute care patients
with diabetic foot ulcers, a condition which affects around 600,000
people in the US each year, and patients with venous leg ulcers,
which currently affect around 2.5 million people in the US. We see
this as a large market that is in need of medical innovation, which
is exactly what DermaPure(TM) provides."
Antony Odell, CEO of Tissue Regenix Group Plc stated: "Tissue
Regenix has managed to establish the US organisation and launch its
first product less than 18 months after forming our North American
subsidiary company, and we are now fully established and ready to
demonstrate the commercial power of dCELL(R). We look forward to
continuing to progress the commercialisation of our unique
technology."
- ENDS -
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Newgate Communications: +44 20 7680 6550
Andrew Adie
Andrew Jones
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement,
wound care and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
About Community Tissue Services
Community Tissue Services, a not-for-profit tissue bank, is an
ethical provider of services to donor families, medical
communities, recipients, and community partners through recovery,
processing and distribution of tissue grafts. Community Tissue
Services complies with guidelines and regulations with the American
Association of Tissue Banks (AATB), Food and Drug and
Administration (FDA) and many other state health department
regulations.
About TASSMA
TASSMA, LLC is a CVE Verified Service Disabled Veteran Owned
Small Business (SDVOSB) based in Buffalo, New York. TASSMA's
mission is to provide governmental business development services to
medical device and equipment manufacturers through a combination of
contract administration and account management activities. As an
SDVOSB supplier to the federal government, TASSMA is able to access
small business programs not generally available to larger corporate
entities, giving our partners a distinct advantage in the federal
marketplace. Todd Staples, a former Marine who served in Operations
Desert Shield/Storm is President and CEO of TASSMA, LLC. "As a
veteran and an employer, there is no greater honor than to serve
our fellow man, especially those who have served. We honor their
sacrifice every single day." www.tassma.net Contact:
info@tassma.net
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFBMITMBMBBTI
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2023 to Aug 2024